+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Cancer refers to a group of diseases in which cells grow out of control and can invade nearby tissues. Because it can develop in almost any organ and often goes unnoticed until advanced stages, one main challenge is early detection. Studies in this a...

Search Bar & Filters

Found 2463 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are studying oral squamous cell carcinoma to evaluate the use of intraoral ultra-high frequency ultrasonography as a diagnostic tool. The goal is to improve visualization of oral soft tissue lesions beyond the mucosal surface, supporting clinical diagnosis with a minimally invasive, repeatable, and cost-effective imaging method. This study focuses on how this ultrasound technique may help assess tumor characteristics in the mouth. Participants diagnosed with oral squamous cell carcinoma and eligible for surgery will undergo an intraoral ultrasound scan using a 70 MHz frequency probe. This device is designed to measure tumor depth of invasion and thickness before surgery, providing detailed imaging of the oral soft tissues. The study involves only this experimental ultrasound procedure for patients meeting the criteria. During the study, participants will receive the ultrasound scan preoperatively to measure the depth of invasion of their tumor. Researchers will collect this measurement as the primary outcome to assess the ultrasounds diagnostic role. The study includes monitoring for safety and adherence, with participants followed until study completion. The total duration and follow-up specifics depend on each participants surgical timeline and study protocols.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are studying the safety, tolerability, and early clinical effects of 177Lu-BetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in adults with relapsed or refractory, locally advanced inoperable, or metastatic solid tumors. This Phase 12a trial aims to find the best dose and observe how the drug behaves in the body, as well as its preliminary impact on tumors. The study includes patients with various solid tumors such as prostate, lung, breast, ovarian, cervical, and others who have progressed after standard treatments. The study has two phases a dose escalation phase to determine the maximum tolerated dose and recommended Phase 2 dose, followed by a dose expansion phase to evaluate initial anti-tumor activity and safety at the selected dose. Participants receive 177Lu-BetaBart intravenously every 6 weeks at increasing doses, either alone or combined with unlabeled BetaBart. Each phase includes a screening period, treatment period, and safety and long-term follow-up. The main treatment period lasts about 22 weeks, excluding long-term monitoring. During the trial, participants undergo various assessments including safety evaluations, tumor imaging, pharmacokinetics, and biochemical response measurements. Researchers monitor side effects, drug distribution, and tumor response over up to 30 weeks. The study team tracks participants health and tumor status through scans and laboratory tests to assess how well the treatment works and how safe it is. Long-term follow-up is also conducted to observe ongoing safety and effects.

Age: 18Years +All GendersPhase 1Phase 2
5 locations
E

Actively Recruiting

This research evaluates the use of a new PET imaging tracer called 18FFAPI-74 for detecting certain types of cancer, including pancreatic ductal adenocarcinoma, cholangiocarcinoma, hepatocellular carcinoma, gastric, bladder, ovarian cancers, pheochromocytomaparaganglioma, small cell lung cancer, extrapulmonary neuroendocrine cancer, mesothelioma, and sarcoma. The study compares the effectiveness of 18FFAPI-74 PET scans to the currently approved imaging methods, such as 18F-FDG PET scans and other standard imaging like CT or MRI, to see if the new tracer can better visualize tumors. Participants receive two baseline PET scans one with the 18FFAPI-74 tracer injected intravenously, followed by imaging about an hour later, and a second scan with the approved 18F-FDG tracer within one week. If the 18FFAPI-74 scan shows tumors, additional scans with this tracer will be done during future routine treatment scans. When the 18F-FDG scan also shows tumors, it will be repeated alongside the 18FFAPI-74 scan. Scans will not be repeated if the 18FFAPI-74 scan does not detect tumors. Scans may be repeated if cancer progresses within two years. During the study, participants will be followed for two years with regular follow-up calls and possible additional PET scans if cancer recurrence or progression is suspected. Researchers will assess the number of lesions detected by scans, tracer uptake levels, and the safety of the 18FFAPI-74 PET imaging procedure. The study aims to improve cancer detection methods and monitor disease progression over time.

Age: 18Years - 120YearsAll GendersPhase 2
1 location
E

Actively Recruiting

Researchers are studying men with metastatic castration-resistant prostate cancer mCRPC to understand how different PETCT scans can predict outcomes during radioligand therapy with 177Lu-PSMA-617. This is an exploratory, prospective study conducted at a single center, focusing on imaging tumor heterogeneity to help assess therapy effects and patient response. The study is designed specifically for Veterans undergoing this treatment. Participants will receive several types of PETCT scans at different times before starting LuPSMA radioligand therapy RLT, and then after the 2nd, 4th, and 6th treatment cycles. These scans include 18F-Fluciclovine PETCT Axumin, 18F-DCFPyL PETCT, and 18F-FDG PETCT. The 18F-Fluciclovine scans will be performed within seven days of the PSMA PET scans to compare imaging results at each time point. During the study, detailed imaging measures such as lesion uptake and tumor volume will be collected and analyzed over time. Patients will be followed at the institution to correlate these imaging results with clinical outcomes. The main outcome measured is the impact of 18F-Fluciclovine PETCT on predicting outcomes of the 177Lu-PSMA-617 therapy from enrollment through 34 weeks of treatment.

Age: 18Years +MALEPhase 4
1 location
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the diagnostic value of a new protein-specific probe called 18F-T2 in PETCT imaging for people with solid tumors that are likely to express high levels of CAIX protein. The study will also assess how safe and tolerable the 18F-T2 injection is, as well as measure its radiation dosage. This research is important to better understand how well 18F-T2 can detect these tumors compared to standard imaging techniques. Participants with tumors suspected to express high levels of CAIX will receive an intravenous injection of 18F-T2. About an hour after the injection, PETCT imaging will be performed to capture detailed images of the tumors. Within one week, participants will also undergo a whole-body PETCT scan using 18F-FDG, a commonly used imaging agent, to allow comparison between the two imaging methods. During the study, participants will be monitored for any adverse events within 24 hours after the 18F-T2 injection to evaluate safety and tolerability. Researchers will measure the diagnostic sensitivity and specificity of 18F-T2 PETCT for detecting CAIX-positive tumors. They will also assess uptake values in tumors on both 18F-T2 and 18F-FDG scans, analyze the correlation between 18F-T2 uptake and CAIX expression in tissue samples, and evaluate radiation dosimetry. The study will continue until one month after completion for outcome assessments.

Age: 18Years +All GendersPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are evaluating the difference between a 5-day course and a 9-day course of whole breast radiation therapy for women with early-stage breast cancer. This phase II randomized trial aims to compare patient satisfaction and side effects from these two radiation schedules to determine if the shorter treatment is as acceptable as the longer one. The study is sponsored by the University of Utah and focuses on women with specific breast cancer types and stages after lumpectomy surgery. Participants will be randomly assigned to receive either 5 fractions or 9 fractions of hypofractionated radiation therapy to the whole breast, with a boost to the tumor area. The radiation treatments are given over the respective number of days, and the study compares these two schedules to assess differences in outcomes. Both groups receive radiation therapy as directed by the study protocol, with no placebo or masking involved. During the study, participants will be followed for several years to evaluate breast satisfaction using Breast-Q scores and to monitor for radiation-related side effects and cancer recurrence. Various assessments will include cosmetic evaluations using photographic scales and patient-reported outcomes collected at multiple time points up to 5 to 8 years. Safety and effectiveness are monitored through adverse event tracking and cancer surveillance, with total study duration extending up to 8 years after treatment.

Age: 18Years +FEMALEPhase 2
1 location
P

Actively Recruiting

Researchers are evaluating two different dosing schedules of the drug 5-Fluorouracil 5-FU as second-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma RM-HNSCC who have already received platinum and PD-1 inhibitor therapies. This phase II trial aims to assess the effectiveness, safety, and side effects of these two regimens. The main goal is to see if either regimen achieves a tumor response rate of at least 10%, measured by standardized criteria. Participants will be randomly assigned to one of two treatment groups. Arm 1 receives 5-FU as a 400 mgm2 bolus followed by a continuous intravenous infusion of 2,400 mgm2 over 46 hours every two weeks, with each cycle lasting 28 days. Arm 2 receives 5-FU as a continuous intravenous infusion of 1,000 mgm2 per day over four days every three weeks, with each cycle lasting 21 days. Dose adjustments may be made based on patient tolerance. Throughout the treatment period, which may last up to four months, participants will be monitored for tumor response, side effects, and treatment interruptions or discontinuations. Researchers will evaluate treatment-related adverse events, dose intensity, and survival outcomes over up to three years and four months following treatment completion. Safety assessments continue for 28 days after treatment ends, ensuring comprehensive monitoring of participants health and response to therapy.

Age: 18Years +All GendersPhase 2
1 location
S

Actively Recruiting

Healthy Volunteer

This research aims to assess the diagnostic value of a new PETCT imaging probe called 68Ga-C1, which specifically targets the CAIX protein found in about 95% of clear cell renal cell carcinomas. The study will also investigate the safety, tolerability, and radiation exposure from 68Ga-C1. Researchers will compare this new imaging method with the standard 18F-FDG PETCT scan in Chinese patients who have unclear kidney masses or confirmed clear cell renal cell carcinoma. Participants with suspected or confirmed clear cell renal cell carcinoma will receive an intravenous injection of 68Ga-C1 at a dose of 0.05-0.10 mCikg, followed by PET imaging. They will also undergo a whole-body 18F-FDG PETCT scan within one week. This approach allows direct comparison of the two imaging techniques in the same patients. During the study, participants will have PETCT scans with both imaging agents to evaluate tumor detection and characteristics. Researchers will measure diagnostic accuracy, radiation dosimetry, and quantitative uptake of 68Ga-C1 over one year. Correlation with tumor pathology will also be assessed. The study will monitor safety and tolerability throughout, with the overall participation lasting at least one year.

Age: 18Years +All GendersPhase Not Applicable
1 location
R

Actively Recruiting

Researchers are evaluating a new radioactive molecular probe called 68Ga-YQ-CC05 that targets the cholecystokinin receptor CCK2R to assess its safety and effectiveness in detecting tumors. This study focuses on patients with medullary thyroid carcinoma, small cell lung cancer, and gastric adenocarcinoma. The goal is to improve early tumor diagnosis using this targeted imaging method. Participants receive an intravenous injection of the 68Ga-YQ-CC05 imaging agent at a dose of 0.05 mCi per kilogram of body weight. PET-CT scans are then performed 60 minutes after the injection to observe tumor uptake of the probe. This imaging technique is compared to other standard methods such as CT and MRI to verify its diagnostic value. During the study, participants undergo PET-CT imaging and provide pathological results to confirm tumor presence. Researchers measure the maximum standardized uptake value SUVmax of the lesion one hour after administration of the probe to evaluate its effectiveness. The study involves monitoring kidney and liver function, blood counts, and patient safety throughout. Total participation time aligns with the imaging and assessment schedule around the injection and scanning procedures.

Age: 18Years - 75YearsAll Genders
1 location
S

Actively Recruiting

Researchers are evaluating the combination of 68Ga-NY104 and 18F-FDG PETCT guided radiation therapy with standard systemic treatment in patients who have metastatic clear cell renal cell carcinoma ccRCC. This phase 2 study focuses on improving treatment outcomes by targeting metastatic lesions more precisely using advanced imaging techniques. The biomarker CAIX, targeted by 68Ga-NY104, has shown promise in detecting ccRCC lesions effectively. Participants will receive radiation therapy planned to cover as many metastatic lesions as possible, guided by baseline PETCT scans using both 68Ga-NY104 and 18F-FDG. Systemic therapy, which may include targeted therapy, immunotherapy, or both, will be given concurrently and determined by the treating urology oncologist. Follow-up 68Ga-NY104 PETCT scans will be done at 6, 12, and 24 months if the tumor is controlled, with additional scans as needed for suspected recurrence. During the study, patients will undergo multiple PETCT scans and other imaging to assess lesion uptake and detection. Researchers will monitor progression-free survival, disease control, overall survival, and adverse events over four years after treatment starts. The study tracks tumor response and safety outcomes while patients continue systemic therapy, with active follow-up for disease status and imaging assessments throughout the trial period.

Age: 18Years +All GendersPhase 2
1 location

1-10 of 2,463

1

Frequently Asked Questions